Ar­row­head touts Phase Ib RNAi da­ta for ccR­CC; PureTech lines up PD-1 from BeiGene for up­com­ing com­bo study

Just days af­ter get­ting wal­loped by the news that an­i­mal tox da­ta forced them to halt an ear­ly-stage cys­tic fi­bro­sis study, Ar­row­head is tout­ing some ini­tial snap­shots from their RNAi treat­ment for clear cell re­nal cell car­ci­no­ma.

Most of the pos­i­tive signs they’re point­ing to re­late to bio­mark­er ac­tiv­i­ty, with an av­er­age 48% re­duc­tion in HIF2α pro­tein among nine evalu­able biop­sy sam­ples. Those re­duc­tions var­ied wide­ly, though, start­ing at 9% and grow­ing to 82%.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.